Toll Free Helpline (India): 1800 1234 070

Rest of World: +91-9810852116

Free Publication Certificate

Vol. 6, Issue 6 (2017)

A clinico-pathological and radiological examination of malignant tumors of the larynx

Author(s):
Dr. Ashish Gupta
Abstract:
Introduction: The larynx has an unique position because it is the major component of the upper respiratory tract and it is located just anterior to the upper end of the digestive tract. It consists of 3 regions - supraglottis, glottis and subglottis. Each region is anatomically and embryologically distinct with separate lymphatic channels. Cancer of each region is therefore different in terms of its presentation, growth patterns, spread, treatment and prognosis. Smoking, tobacco and alcohol are the major risk factors of the tumor of larynx. Materials and Methods: It is a hospital based study conducted on 50 patients of laryngeal tumor which showed that most of the patients were male and they had carcinoma on the left of the larynx than the right. Hoarseness and foreign body/sticky sensation in the throat were the most common presenting symptoms. The follow up period of a minimum of five to eight years is necessary to evaluate the survival rates, morbidity, and the correct, exact outcome of the treatment modality for management of laryngeal malignancy. Result: The peak incidence of cancer occurred in the 60-70 (38.8%) year age group followed by the 51-60 (22.3%) year age group 90% of the patients were male. The male to female ratio was 9:1. According to the occupation statistics, Farmers constituted 55.5% of patients. Conclusion: In conclusion an integrated diagnostic and treatment program is necessary for patients with Malignant Tumors of the Larynx because various factors are responsible for the disease. Still the major risk factor of the tumor is tobacco and alcohol.
Pages: 209-212  |  226 Views  49 Downloads


The Pharma Innovation Journal
How to cite this article:
Dr. Ashish Gupta. A clinico-pathological and radiological examination of malignant tumors of the larynx. Pharma Innovation 2017;6(6):209-212.

Call for book chapter